BIPH: The announcement didn't give many details....and BSX didn't do a joint PR....but BIPH's CEO has made it clear BIPH didn't want to be BSX's bi***….so that’s probably part of the reason why there was no joint-PR.
All the details of milestone payments, royalty rates, and which of BIPH's "multiple patents" will be applied to which of BSX's "exclusive and non-exclusive product categories" remain concealed.....but THE AGREEMENT HAS BEEN EXECUTED...FINALLY!!!
The fact that they’re waiting for “confirmation of paperwork related to recent acquisitions” leads me to believe this deal does involve stents….since that was pretty much AMRIS’s bread and butter.
Maybe BSX will be ready for a joint-PR when they’re ready to fund the agreements?:
“Funding under both agreements is expected to occur following confirmation of paperwork related to our recent acquisitions.”
But investors will probably never know for sure what products are involved until BSX starts introducing "game changing" products that include BIPH's technologies.
Congratulations all BIPH longs!
"Our houses are such unwieldy property that we are often imprisoned rather than housed in them." - Henry David Thoreau, Walden: Economy, 1854
